HR 5197 · in committee · significant
Protect Beneficiaries from Middlemen Act
- healthcare
What this bill does
- This bill caps what Medicare patients pay for prescription drugs at the lower of the average net price or cash price.
- Medicare beneficiaries and Medicare Advantage enrollees are affected by the cost-sharing changes.
- The Government Accountability Office must report on how the bill is implemented.
Generated by claude-haiku-4-5
Community Threads
Started by Cosponsor
- 01
How would capping patient costs at the lower of average net price or cash price affect pharmaceutical companies' pricing strategies and drug development incentives?
- 02
Which Medicare beneficiaries would see the most significant savings under this bill, and could it create disparities between different enrollment types?
- 03
What unintended consequences might arise if patients pay less than insurers' negotiated prices, and how could this affect the overall Medicare drug market?
Cosponsor writes these to seed civic discussion — they aren't user posts. Sign in to reply.
Sponsor · R-NY-11
Nicole Malliotakis
Citizen cosponsors
0
In Congress
0/ 435
House Reps cosponsoring
Introduced 2025-09-08
Legislative timeline
2025-09-08 · house · IntroReferral
Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
2025-09-08 · house · IntroReferral
Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
2025-09-08 · IntroReferral
Introduced in House
2025-09-08 · IntroReferral
Introduced in House
Citizen comments
Sign in to comment on this bill.
No comments yet — be the first.